Comparative evaluation of ERα and ERβ significance in breast cancer: state of the art

References

• Jensen EV, Jordan VC. The estrogen receptor: a model for molecular medicine. Clin. Cancer Res.9, 1980–1989 (2003).
   PubMed Web of Science ®Google Scholar
• Dennis AP, O’Malley BW. Rush hour at the promoter: how the ubiquitin–proteasome pathway polices the traffic flow of nuclear receptor-dependent transcription. J. Steroid Biochem. Mol. Biol.93, 139–151 (2005).
   PubMedGoogle Scholar
• McKenna NJ, Lanz RB, O’Malley BW. Nuclear receptor coregulators: cellular and molecular biology. Endocrine Rev.20, 321–344 (1999).
   PubMed Web of Science ®Google Scholar
• Shibata H, Spencer TE, Onate SA et al. Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action. Recent Prog. Horm. Res.52, 141–164; discussion 64–65 (1997).
   PubMedGoogle Scholar
• Xu W. Nuclear receptor coactivators: the key to unlock chromatin. Biochem. Cell Biol.83, 418–428 (2005).
   PubMedGoogle Scholar
• Metivier R, Penot G, Hubner MR et al. Estrogen receptor-α directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell115, 751–763 (2003).
   PubMed Web of Science ®Google Scholar
• Smith CL, O’Malley BW. Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocrine Rev.25, 45–71 (2004).
   PubMed Web of Science ®Google Scholar
• Hall JM, McDonnell DP. Coregulators in nuclear estrogen receptor action – from concept to therapeutic targeting. Mol. Interv.5, 343–357 (2005).
   PubMed Web of Science ®Google Scholar
• Carroll JS, Meyer CA, Song J et al. Genome-wide analysis of estrogen receptor binding sites. Nat. Genet.38, 1289–1297 (2006).
   PubMed Web of Science ®Google Scholar
• Fullwood MJ, Liu MH, Pan YF et al. An oestrogen-receptor-α-bound human chromatin interactome. Nature462, 58–64 (2009).
   PubMed Web of Science ®Google Scholar
• Frasor J, Chang EC, Komm B et al. Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome. Cancer Res.66, 7334–7340 (2006).
   PubMed Web of Science ®Google Scholar
• Frasor J, Danes JM, Komm B et al. Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology144, 4562–4574 (2003).
   PubMed Web of Science ®Google Scholar
• Frasor J, Stossi F, Danes JM, Komm B, Lyttle CR, Katzenellenbogen BS. Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells. Cancer Res.64, 1522–1533 (2004).
   PubMed Web of Science ®Google Scholar
• Ellison-Zelski SJ, Solodin NM, Alarid ET. Repression of ESR1 through actions of estrogen receptor α and Sin3A at the proximal promoter. Mol. Cell. Biol.29, 4949–4958 (2009).
   PubMed Web of Science ®Google Scholar
• Malik S, Jiang S, Garee JP et al. Histone deacetylase 7 and FoxA1 in estrogen-mediated repression of RPRM. Mol. Cell. Biol.30, 399–412 (2010).
   PubMedGoogle Scholar
• Stossi F, Madak-Erdogan Z, Katzenellenbogen BS. Estrogen receptor α represses transcription of early target genes via p300 and CtBP1. Mol. Cell. Biol.29, 1749–1759 (2009).
   PubMedGoogle Scholar
• Welboren WJ, Sweep FCGJ, Span PN, Stunnenberg HG. Genomic actions of estrogen receptor α: what are the targets and how are they regulated? Endocr. Relat. Cancer16, 1073–1089 (2009).
   PubMed Web of Science ®Google Scholar
• Marino M, Galluzzo P, Ascenzi P. Estrogen signaling multiple pathways to impact gene transcription. Curr. Genomics7, 497–508 (2006).
   PubMed Web of Science ®Google Scholar
• Song RXD, Fan P, Yue W, Chen YC, Santen RJ. Role of receptor complexes in the extranuclear actions of estrogen receptor α in breast cancer. Endocr. Relat. Cancer13, S3–S13 (2006).
   Google Scholar
• Prossnitz ER, Maggiolini M. Mechanisms of estrogen signaling and gene expression via GPR30. Mol. Cell. Endocrinol.308, 32–38 (2009).
   PubMed Web of Science ®Google Scholar
• Jordan VC. SERMs: meeting the promise of multifunctional medicines. J. Natl Cancer Inst.99, 350–356 (2007).
   PubMed Web of Science ®Google Scholar
• Orlando L, Schiavone P, Fedele P et al. Molecularly targeted endocrine therapies for breast cancer. Cancer Treat. Rev.36(Suppl. 3), S67–S71 (2010).
   PubMed Web of Science ®Google Scholar
• Jordan VC, Morrow M. Tamoxifen, raloxifene, and the prevention of breast cancer. Endocr. Rev.20, 253–278 (1999).
   PubMed Web of Science ®Google Scholar
• Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl Cancer Inst.90, 1371–1388 (1998).
   PubMed Web of Science ®Google Scholar
• Fisher B, Powles TJ, Pritchard KJ. Tamoxifen for the prevention of breast cancer. Eur. J. Cancer36, 142–150 (2000).
   PubMed Web of Science ®Google Scholar
• Krecsak L, Micsik T, Kiszler G et al. Technical note on the validation of a semi-automated image analysis software application for estrogen and progesterone receptor detection in breast cancer. Diagn. Pathol.6, 6 (2011).
   PubMedGoogle Scholar
• Townson SM, O’Connell P. Identification of estrogen receptor α variants in breast tumors: implications for predicting response to hormonal therapies. J. Surg. Oncol.94, 271–273 (2006).
   PubMedGoogle Scholar
• Poulard C, Bouchekioua-Bouzaghou K, Sentis S, Corbo L, Le Romancer M. [Post-translational modifications modulate estrogen receptor α activity in breast tumors]. Med. Sci. (Paris)26, 636–640 (2011).
   Google Scholar
• Santen RJ, Fan P, Zhang Z, Bao Y, Song RX, Yue W. Estrogen signals via an extra-nuclear pathway involving IGF-1R and EGFR in tamoxifen-sensitive and -resistant breast cancer cells. Steroids74, 586–594 (2009).
   PubMed Web of Science ®Google Scholar
• Wu RC, Smith CL, O’Malley BW. Transcriptional regulation by steroid receptor coactivator phosphorylation. Endocr. Rev.26, 393–399 (2005).
   PubMed Web of Science ®Google Scholar
• Hammond ME, Hayes DF, Dowsett M et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J. Clin. Oncol.28, 2784–2795 (2010).
   PubMed Web of Science ®Google Scholar
• Albergaria A, Paredes J, Sousa B et al. Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours. Breast Cancer Res.11, R40 (2009).
   PubMed Web of Science ®Google Scholar
• Jacquemier J, Charafe-Jauffret E, Monville F et al. Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer. Breast Cancer Res.11, R23 (2009).
   Web of Science ®Google Scholar
• Tozlu S, Girault I, Vacher S et al. Identification of novel genes that co-cluster with estrogen receptor α in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach. Endocr. Relat. Cancer13, 1109–1120 (2006).
   PubMedGoogle Scholar
• Oesterreich S, Lee AV, Davidson NE. Is it time to ReSET the standard for estrogen receptor testing in breast cancer? J. Clin. Oncol.28, 4101–4103 (2010).
   PubMedGoogle Scholar
• Symmans WF, Hatzis C, Sotiriou C et al. Genomic index of sensitivity to endocrine therapy for breast cancer. J. Clin. Oncol.28, 4111–4119 (2010).
   PubMed Web of Science ®Google Scholar
• Kim C, Paik S. Gene-expression-based prognostic assays for breast cancer. Nat. Rev. Clin. Oncol.7, 340–347 (2010).
   PubMed Web of Science ®Google Scholar
• O’Toole S A, Selinger CI, Millar EK, Lum T, Beith JM. Molecular assays in breast cancer pathology. Pathology43, 116–127 (2011).
   PubMedGoogle Scholar
• Speirs V, Skliris G, Burdall S, Carder P. Distinct expression patterns of ERα and ERβ in normal human mammary gland. J. Clin. Pathol.255, 371–374 (2002).
   Google Scholar
• Clarke R, Howell A, Potten C, Anderson E. Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res.57, 4987–4991 (1997).
   PubMed Web of Science ®Google Scholar
• Couse J, Korach K. Estrogen receptor null mice: what have we learned and where will they lead us ? Endocrine Rev.20, 358–417 (1999).
   PubMed Web of Science ®Google Scholar
• Forster C, Makela S, Warri A et al. Involvement of estrogen receptor β in terminal differentiation of mammary gland epithelium. Proc. Natl Acad. Sci. USA99, 15578–15583 (2002).
   PubMed Web of Science ®Google Scholar
• Couse JF, Yates MM, Deroo BJ, Korach KS. Estrogen receptor-β is critical to granulosa cell differentiation and the ovulatory response to gonadotropins. Endocrinology146, 3247–3262 (2005).
   PubMed Web of Science ®Google Scholar
• Leygue E, Dotzlaw H, Watson P, Murphy L. Altered estrogen receptor α and β mRNA expression during human breast tumorigenesis. Cancer Res.58, 3197–3201 (1998).
   PubMed Web of Science ®Google Scholar
• Roger P, Sahla M, Makela S, Gustafsson JA, Baldet P, Rochefort H. Decreased expression of estrogen receptor β protein in proliferative preinvasive mammary tumors. Cancer Res.61, 2537–2541 (2001).
   PubMed Web of Science ®Google Scholar
• Skliris G, Munot K, Bell S, Carder P et al. Reduced expression of oestrogen receptor β in invasive breast cancer and its re-expression using DNA methyltransferase inhibitors in a cell line model. J. Pathol.201, 213–220 (2003).
   PubMed Web of Science ®Google Scholar
• Bardin A, Boulle N, Lazennec G, Vignon F, Pujol P. Loss of ERβ expression as a common step in estrogen-dependent tumor progression. Endocr. Relat. Cancer11, 537–551 (2004).
   PubMed Web of Science ®Google Scholar
• Zhu X, Leav I, Leung YK et al. Dynamic regulation of estrogen receptor-β expression by DNA methylation during prostate cancer development and metastasis. Am. J. Pathol.164, 2003–2012 (2004).
   PubMed Web of Science ®Google Scholar
• Murphy L, Watson P. Is oestrogen receptor-β a predictor of endocrine therapy responsiveness in human breast cancer? Endocrine Relat. Cancer13, 327–334 (2006).
   PubMedGoogle Scholar
• Fox E, Davis R, Shupnik M. ERβ in breast cancer – onlooker, passive player, or active protector? Steroids73, 1039–1051 (2008).
   PubMed Web of Science ®Google Scholar
• Weitsman G, Skliris G, Ung K et al. Assessment of multiple different oestrogen receptor β antibodies for their ability to immunoprecipitate under chromatin immunoprecipitation conditions. Breast Cancer Res. Treat.100, 23–31 (2006).
   PubMedGoogle Scholar
• Skliris G, Leygue E, Curtis-Snell L, Watson P, Murphy L. Expression of oestrogen receptor-β in oestrogen receptor-α negative human breast tumours. Br. J. Cancer95, 616–626 (2006).
   PubMedGoogle Scholar
• Monroe D, Secreto F, Subramaniam M, Getz B, Khosla S, Spelsberg T. Estrogen receptor α and β heterodimers exert unique effects on estrogen- and tamoxifen-dependent gene expression in human U2OS osteosarcoma cells. Mol. Endocrinol.19, 1555–1568 (2005).
   PubMed Web of Science ®Google Scholar
• Warner M, Gustafsson JA. The role of estrogen receptor β (ERβ) in malignant diseases – a new potential target for antiproliferative drugs in prevention and treatment of cancer. Biochem. Biophys. Res. Commun.396, 63–66 (2010).
   PubMed Web of Science ®Google Scholar
• Moore J, McKee D, Slentz-Kesler K et al. Cloning and characterization of human estrogen receptor β isoforms. Biochem. Biophys. Res. Commun.247, 75–78 (1998).
   PubMed Web of Science ®Google Scholar
• Chi A, Chen X, Chirala M, Younes M. Differential expression of estrogen receptor β isoforms in human breast cancer tissue. Anticancer Res.23, 211–216 (2003).
   PubMedGoogle Scholar
• Saji S, Omoto Y, Shimizu C et al. Expression of estrogen receptor (ER) βcx protein in ERα-positive breast cancer: specific correlation with progesterone receptor. Cancer Res.62, 4849–4853 (2002).
   PubMed Web of Science ®Google Scholar
• Saunders P, Millar M, Macpherson S et al. ERβ1 and the ERβ2 splice variant (ERβcx/β2) are expressed in distinct cell populations in the adult human testis. J. Clin. Endocrinol. Metab.87, 2706–2715 (2002).
   PubMed Web of Science ®Google Scholar
• Saunders PT, Millar MR, Williams K et al. Expression of oestrogen receptor β (ERβ1) protein in human breast cancer biopsies. Br. J. Cancer86, 250–256 (2002).
   PubMedGoogle Scholar
• Shaaban AM, Green AR, Karthik S et al. Nuclear and cytoplasmic expression of ERβ1, ERβ2, and ERβ5 identifies distinct prognostic outcome for breast cancer patients. Clin. Cancer Res.14, 5228–5235 (2008).
   PubMed Web of Science ®Google Scholar
• Yan M, Rayoo M, Takano EA, Fox SB. Nuclear and cytoplasmic expressions of ERβ1 and ERβ2 are predictive of response to therapy and alters prognosis in familial breast cancers. Breast Cancer Res. Treat.126(2), 395–405 (2010).
   PubMedGoogle Scholar
• Herynk M, Fuqua S. Estrogen receptor mutations in human disease. Endocr. Rev.25, 869–898 (2004).
   PubMed Web of Science ®Google Scholar
• Leygue E, Dotzlaw H, Lu B, Glor C, Watson P, Murphy L. Estrogen receptor-β: mine is longer than yours ? J. Clin. Endocrinol. Metab.83, 3754–3755 (1998).
   PubMed Web of Science ®Google Scholar
• Mosselman S, Polman J, Dijkema R. ER-β: identification and characterization of a novel human estrogen receptor. FEBS Lett.392, 49–53 (1996).
   PubMed Web of Science ®Google Scholar
• Kuiper G, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc. Natl Acad. Sci. USA93, 5925–5930 (1996).
   PubMed Web of Science ®Google Scholar
• Hirata S, Shoda T, Kato J, Hoshi K. The multiple untranslated first exons system of the human estrogen receptor β (ER β) gene. J. Steroid Biochem. Mol. Biol.78, 33–40 (2001).
   PubMedGoogle Scholar
• Savinov A, Remacle A, Golubkov V et al. Matrix metalloproteinase 26 proteolysis of the NH2-terminal domain of the estrogen receptor β correlates with the survival of breast cancer patients. Cancer Res.66, 2716–2724 (2006).
   PubMed Web of Science ®Google Scholar
• Tateishi Y, Sonoo R, Sekiya Y et al. Turning off estrogen receptor β-mediated transcription requires estrogen-dependent receptor proteolysis. Mol. Cell. Biol.26, 7966–7976 (2006).
   PubMedGoogle Scholar
• Fuqua S, Cui Y, Lee A, Osborne C, Horwitz K. Insights into the role of progesterone receptors in breast cancer. J. Clin. Oncol.23, 931–932 (2005).
   PubMedGoogle Scholar
• Hopp TA, Weiss HL, Hilsenbeck SG et al. Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates. Clin. Cancer Res.10, 2751–2760 (2004).
   PubMed Web of Science ®Google Scholar
• Skliris G, leygue E, Watson P, Murphy L. Estrogen receptor α negative breast cancer patients: estrogen receptor β as a therapeutic target. J. Steroid Biochem. Mol. Biol.109, 1–10 (2008).
   PubMed Web of Science ®Google Scholar
• Fuqua S, Schiff R, Parra I et al. Expression of wild-type estrogen receptor β and variant isoforms in human breast cancer. Cancer Res.59, 5425–5428 (1999).
   PubMed Web of Science ®Google Scholar
• Skliris GP, Nugent ZJ, Rowan BG, Penner CR, Watson PH, Murphy LC. A phosphorylation code for oestrogen receptor-α predicts clinical outcome to endocrine therapy in breast cancer. Endocr. Relat. Cancer17, 589–597 (2010).
   PubMedGoogle Scholar
• Murphy LC, Seekallu SV, Watson PH. Clinical significance of estrogen receptor phosphorylation. Endocr. Relat. Cancer18, R1–R14 (2011).
   Web of Science ®Google Scholar
• Sanchez M, Picard N, Sauve K, Tremblay A. Challenging estrogen receptor β with phosphorylation. Trends Endocrinol. Metab.21, 104–110 (2010).
   PubMedGoogle Scholar
• Hamilton-Burke W, Coleman L, Cummings M et al. Phosphorylation of estrogen receptor β at serine 105 is associated with good prognosis in breast cancer. Am. J. Pathol.177, 1079–1086 (2010).
   PubMedGoogle Scholar
• Zhao C, Dahlman-Wright K, Gustafsson JA. Estrogen signaling via estrogen receptor β. J. Biol. Chem.285, 39575–39579 (2010).
   PubMed Web of Science ®Google Scholar
• Zhao C, Gao H, Liu Y et al. Genome-wide mapping of estrogen receptor-β-binding regions reveals extensive cross-talk with transcription factor activator protein-1. Cancer Res.70, 5174–5183 (2010).
   PubMed Web of Science ®Google Scholar
• Murphy L, Peng B, Lewis A et al. Inducible upregulation of oestrogen receptor-β1 affects oestrogen and tamoxifen responsiveness in MCF7 human breast cancer cells. J. Mol. Endocrinol.34, 553–566 (2005).
   PubMedGoogle Scholar
• Chang EC, Frasor J, Komm B, Katzenellenbogen BS. Impact of estrogen receptor β on gene networks regulated by estrogen receptor α in breast cancer cells. Endocrinology147, 4831–4842 (2006).
   PubMed Web of Science ®Google Scholar
• Paruthiyil S, Parmar H, Kerekatte V, Cunha G, Firestone G, Leitman D. Estrogen receptor b inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res.64, 423–428 (2004).
   PubMed Web of Science ®Google Scholar
• Lazennec G, Bresson D, Lucas A, Chauveau C, Vignon F. ERβ inhibits proliferation and invasion of breast cancer cells. Endocrinology142, 4120–4130 (2001).
   PubMed Web of Science ®Google Scholar
• Tonetti D, Rubenstein R, Deleon M et al. Stable transfection of an estrogen receptor β cDNA isofrm into MDAMB231 breast cancer cells. J. Steroid Biochem. Mol. Biol.87, 47–55 (2003).
   PubMedGoogle Scholar
• Hou Y, Yuan S, Li H et al. ERβ exerts multiple stimulative effects on human breast carcinoma cells. Oncogene23, 5799–5806 (2004).
   PubMedGoogle Scholar
• Skliris G, Lewis A, Emberley E et al. Estrogen receptor-β regulates psoriasin (S100A7) in human breast cancer. Breast Cancer Res. Treat.104, 75–85 (2007).
   PubMed Web of Science ®Google Scholar
• Choi Y, Pinto M. Estrogen receptor β in breast cancer: associations between ERβ, hormonal receptors, and other prognostic biomarkers. Appl. Immunohistochem. Mol. Morphol.13, 19–24 (2005).
   PubMedGoogle Scholar
• Lewandowski S, Thiery J, Jalil A, Leclercq G, Szczylik C, Chouaib S. Opposite effects of estrogen receptors α and β on MCF-7 sensitivity to the cytotoxic action of TNF and p53 activity. Oncogene24, 4789–4798 (2005).
   PubMedGoogle Scholar
• Bhat R, Harnish DC, Stevis P, Lyttle C, Komm B. A novel human estrogen receptor β: identification and functional analysis of additional N-terminal amino acids. J. Steroid Biochem. Mol. Biol.67, 233–240 (1998).
   PubMedGoogle Scholar
• Gilmore T, Herscovitch M. Inhibitors of NF-κB signaling: 785 and counting. Oncogene25, 6887–6899 (2006).
   PubMed Web of Science ®Google Scholar
• Cvoro A, Tatomer D, Tee M, Zogovic T, Harris H, Leitman D. Selective estrogen receptor-β agonists repress transcription of proinflammatory genes. J. Immunol.180, 630–636 (2008).
   PubMed Web of Science ®Google Scholar
• Harris H, Albert L, Leathurby Y et al. Evaluation of an estrogen receptor-β agonist in animal models of human disease. Endocrinology144, 4241–4249 (2003).
   PubMed Web of Science ®Google Scholar
• Ogawa S, Inoue S, Watanabe T et al. Molecular cloning and characterization of human estrogen receptor bcx: potential inhibitor of estrogen action in human. Nucleic Acids Res.26, 3505–3512 (1998).
   PubMed Web of Science ®Google Scholar
• Leung Y, Mak P, Hassan S, Ho S. Estrogen receptor (ER)-β isoforms: a key to understanding ER-β signaling. Proc. Natl Acad. Sci. USA.103, 13162–13167 (2006).
   PubMed Web of Science ®Google Scholar
• Peng B, Lu B, Leygue E, Murphy L. Putative functional characteristics of human estrogen receptor-β isoforms. J. Mol. Endocrinol.30, 13–29 (2003).
   PubMed Web of Science ®Google Scholar
• Inoue S, Ogawa S, Horie K et al. An estrogen receptor β isoform that lacks exon 5 has dominant negative activity on both ERα and ERβ. Biochem. Biophys. Res. Commun.279, 814–819 (2000).
   PubMed Web of Science ®Google Scholar
• Treeck O, Juhasz-Boess I, Lattrich C, Horn F, Goerse R, Ortmann O. Effects of exon-deleted estrogen receptor β transcript variants on growth, apoptosis and gene expression of human breast cancer cell lines. Breast Cancer Res. Treat.110, 507–520 (2008).
   PubMed Web of Science ®Google Scholar
• Weihua Z, Saji S, Makinen S et al. Estrogen receptor (ER) β, a modulator of ERα in the uterus. Proc. Natl Acad. Sci. USA97, 5936–5941 (2000).
   PubMed Web of Science ®Google Scholar
• Grober OM, Mutarelli M, Giurato G et al. Global analysis of estrogen receptor β binding to breast cancer cell genome reveals an extensive interplay with estrogen receptor α for target gene regulation. BMC Genomics12, 36 (2011).
   PubMed Web of Science ®Google Scholar
• Secreto FJ, Monroe DG, Dutta S, Ingle JN, Spelsberg TC. Estrogen receptor α/β isoforms, but not βcx, modulate unique patterns of gene expression and cell proliferation in Hs578T cells. J. Cell. Biochem.101, 1125–1147 (2007).
   PubMed Web of Science ®Google Scholar
• Williams C, Edvardsson K, Lewandowski SA, Strom A, Gustafsson JA. A genome-wide study of the repressive effects of estrogen receptor β on estrogen receptor α signaling in breast cancer cells. Oncogene27, 1019–1032 (2008).
   PubMedGoogle Scholar
• Charn TH, Liu ET, Chang EC, Lee YK, Katzenellenbogen JA, Katzenellenbogen BS. Genome-wide dynamics of chromatin binding of estrogen receptors α and β: mutual restriction and competitive site selection. Mol. Endocrinol.24, 47–59 (2010).
   PubMedGoogle Scholar
• Reid G, Hubner M, Metivier R et al. Cyclic, proteasome-mediated turnover of unliganded and liganded ERα on responsive promoters is an integral feature of estrogen signaling. Mol. Cell.11, 695–707 (2003).
   PubMed Web of Science ®Google Scholar
• Tee MK, Rogatsky I, Tzagarakis-Foster C et al. Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors α and β. Mol. Biol. Cell.15, 1262–1272 (2004).
   PubMed Web of Science ®Google Scholar
• Vivar OI, Zhao X, Saunier EF et al. Estrogen receptor β binds to and regulates three distinct classes of target genes. J. Biol. Chem.285, 22059–22066 (2010).
   PubMed Web of Science ®Google Scholar
• Gruvberger-Saal S, Bendahl P, Saal L et al. Estrogen receptor β expression is associated with tamoxifen response in ERα-negative breast carcinoma. Clin. Cancer Res.13, 1987–1994 (2007).
   PubMed Web of Science ®Google Scholar
• Sorlie T, Perou C, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA98, 10869–10874 (2001).
   PubMed Web of Science ®Google Scholar
• Speirs V. Oestrogen receptor β in breast cancer: good, bad or still too early to tell? J. Pathol.197, 143–147 (2002).
   PubMed Web of Science ®Google Scholar
• Cummings M, Iremonger J, Green CA, Shaaban AM, Speirs V. Gene expression of ERβ isoforms in laser microdissected human breast cancers, implications for gene expression analyses. Cell Oncol.31, 467–473 (2009).
   PubMedGoogle Scholar
• Yamashita H, Takahashi S, Ito Y et al. Predictors of response to exemestane as primary endocrine therapy in estrogen receptor-positive breast cancer. Cancer Sci.100, 2028–2033 (2009).
   PubMedGoogle Scholar
• Motomura K, Ishitobi M, Komoike Y et al. Expression of estrogen receptor β and phosphorylation of estrogen receptor α serine 167 correlate with progression-free survival in patients with metastatic breast cancer treated with aromatase inhibitors. Oncology79, 55–61 (2010).
   PubMedGoogle Scholar
• Novelli F, Milella M, Melucci E et al. A divergent role for estrogen receptor-β in node-positive and node-negative breast cancer classified according to molecular subtypes, an observational prospective study. Breast Cancer Res.10, R74 (2008).
   Google Scholar
• Leav I, Lau KM, Adams J et al. Comparative studies of the estrogen receptor β and α and the androgen receptor in normal human prostate glands, dysplasia and in primary and metastatic carcinoma. Am. J. Pathol.159, 79–92 (2001).
   PubMed Web of Science ®Google Scholar
• Horvath L, Henshall S, Lee C-S et al. Frequent loss of estrogen receptor β expression in prostate cancer. Cancer Res.61, 5331–5335 (2001).
   PubMed Web of Science ®Google Scholar
• Bierie B, Moses HL. Gain or loss of TGFβ signaling in mammary carcinoma cells can promote metastasis. Cell Cycle8, 3319–3327 (2009).
   PubMed Web of Science ®Google Scholar
• Palmieri C, Lam E, Mansi J et al. The expression of ERβcx in human breast cancer and the relationship to endocrine therapy and survival. Clin. Cancer Res.10, 2421–2428 (2004).
   PubMedGoogle Scholar
• Omoto Y, Kobayashi S, S Inoue S et al. Evaluation of oestrogen receptor β wild-type and variant protein expression, and relationship with clinicopathological factors in breast cancers. Eur. J. Cancer38, 380–386 (2002).
   PubMed Web of Science ®Google Scholar
• Vinayagam R, Sibson DR, Holcombe C, Aachi V, Davies MP. Association of oestrogen receptor β 2 (ERβ2/ERβcx) with outcome of adjuvant endocrine treatment for primary breast cancer – a retrospective study. BMC Cancer7, 131 (2007).
   PubMedGoogle Scholar
• Sugiura H, Toyama T, Hara Y et al. Expression of estrogen receptor β wild-type and its variant ERβcx/β2 is correlated with better prognosis in breast cancer. Jpn. J. Clin. Oncol.37, 820–828 (2007).
   PubMedGoogle Scholar
• Esslimani-Sahla M, Simony-Lafontaine J, Kramar A et al. Estrogen receptor β (ERβ) level but not its ERβ-cx variant helps to predict tamoxifen resistance in breast cancer. Clin. Cancer Res.10, 5769–5776 (2004).
   PubMedGoogle Scholar
• Miller W, Anderson T, Dixon J, Saunders P. Oestrogen receptor β and neoadjuvant therapy with tamoxifen: prediction of response and effects of treatment. Br. J. Cancer94, 1333–1338 (2006).
   PubMedGoogle Scholar
• O’Neill P, Davies M, Shaaban A et al. Wild-type oestrogen receptor β (ERβ1) mRNA and protein expression in tamoxifen-treated post-menopausal breast cancers. Br. J. Cancer91, 1694–1702 (2004).
   PubMedGoogle Scholar
• Jensen E, Cheng G, Palmieri C et al. Estrogen receptors and proliferation markers in primary and recurrent breast cancer. Proc. Natl Acad. Sci. USA98, 15197–15202 (2001).
   PubMed Web of Science ®Google Scholar
• Honma N, Horii R, Iwase T et al. Clinical importance of estrogen receptor-β evaluation in breast cancer patients treated with adjuvant tamoxifen therapy. J. Clin. Oncol.26, 3727–3734 (2008).
   PubMedGoogle Scholar
• Sengupta S, Jordan VC. Selective estrogen modulators as an anticancer tool, mechanisms of efficiency and resistance. Adv. Exp. Med. Biol.630, 206–219 (2008).
   PubMed Web of Science ®Google Scholar
• Jordan VC, Lewis-Wambi JS, Patel RR, Kim H, Ariazi EA. New hypotheses and opportunities in endocrine therapy, amplification of oestrogen-induced apoptosis. Breast18, S10–S17 (2009).
   Google Scholar